New insider activity at Immunome ( (IMNM) ) has taken place on March 31, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunome’s President and CEO, Clay Siegall, has demonstrated confidence in the company by purchasing 25,450 shares of Immunome stock in a single transaction, with the buy valued at $500,601.
Recent Updates on IMNM stock
Immunome shares saw active analyst revisions over the last day as firms digested Q4 and FY25 updates, though the stock traded mainly on expectations rather than surprises. Lake Street and Stephens trimmed targets after recalibrating models to refreshed Q4 metrics and guidance, while still citing solid execution and an extended cash runway into 2028.
By contrast, Craig-Hallum and JPMorgan lifted their targets, emphasizing a shift from binary trial risk toward execution on varegacestat’s planned NDA, strong Phase 3 RINGSIDE data in desmoid tumors, and a strengthened balance sheet that they believe limits downside. Both also pointed to the advancing ADC pipeline, with ongoing IM-1021 work and multiple INDs expected in 2026, as key longer-term valuation drivers.
Spark’s Take on IMNM Stock
According to Spark, TipRanks’ AI Analyst, IMNM is a Neutral.
The score is held back primarily by persistent losses, declining revenue, and significant cash burn despite a strong low-debt balance sheet. Technicals are currently weak versus short-term averages with negative MACD, and valuation signals remain constrained by negative earnings. Offsetting these risks, corporate developments are a notable positive, led by strong Phase 3 results and improved funding capacity from the follow-on offering.
To see Spark’s full report on IMNM stock, click here.
More about Immunome
YTD Price Performance: -10.15%
Average Trading Volume: 1,546,531
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B